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Abstract 
The number of children taking second-generation antipsychotics (SGA) is increasing. While 
SGAs produce fewer neurological side effects, the metabolic side effects of SGAs increase the 
risk for future cardiometabolic disease. In 2011, the American Academy of Child and Adolescent 
Psychiatry endorsed following guidelines established in 2004 recommending that people taking 
SGAs receive regular metabolic screening including waist circumference measurement, fasting 
blood glucose, and fasting lipids. Despite recommendations, studies have shown that children do 
not receive routine metabolic monitoring. Provider attitudes toward following guidelines can 
influence the rates of monitoring. Research suggests that monitoring rates improve after 
psychiatric providers receive educational programs on SGA use and recommended guidelines. In 
response to these findings, an evidence-based educational intervention discussing SGA use in 
children and recommended metabolic monitoring was proposed to increase the rates of metabolic 
monitoring in a community-based psychiatric practice that treats children. While no results were 
statistically significant, the average attitude score of providers toward following guidelines was 
higher post-education and the proportion of providers who ordered screening tests post-education 
increased. To further improve metabolic monitoring, it is recommended that interventions 
designed to increase the subjective norms and perceived behavioral control of providers be 
implemented. The main limitations of this project were the small sample size and the use of self-
reports to assess provider ordering of screening tests.  
 
Keywords: second-generation antipsychotics, atypical antipsychotics, metabolic monitoring, 
waist circumference.  
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Metabolic Monitoring in Children and Adolescents Receiving Second-Generation Antipsychotics 
The use of second-generation antipsychotics (SGA) to treat psychiatric illness in children 
and adolescents has been increasing. Between the years of 1992 and 2002 in the United States, 
there was a six-fold increase in the number of office-based visits in which a child or adolescent 
received an antipsychotic prescription (Panagiotopoulos, Ronsley, Elbe, Davidson, & Smith, 
2010; Panagiotopoulos, Ronsley, Kuzeljevic, & Davidson, 2012). By 2009, SGAs were being 
prescribed to children and adolescents at the same frequency as they were being prescribed to 
adults (Connolly, Toomey, & Schneeweiss, 2015). Despite the increased use of SGAs, however, 
many providers are not following current recommendations for metabolic monitoring (Connolly 
et al, 2015; Morrato et al., 2010). 
Background and Significance 
Second-generation or atypical antipsychotic use in children has been rapidly increasing 
(De Hert et al., 2011; Olfson, Blanco, Liu, Moreno, & Laje, 2006; Panagiotopoulos et al., 2010).  
SGAs are prescribed for a variety of psychiatric illnesses in children and adolescents including 
bipolar disorder, schizophrenia and other psychotic disorders, mood disorders, pervasive 
developmental disorders, and disruptive behavior disorders (Connolly et al., 2015; De Hert et al., 
2011; Olfson et al., 2006). While the Food and Drug Administration (FDA) has approved the use 
of certain SGAs for the treatment of select psychiatric disorders in children and adolescents, 
SGAs continue to be prescribed off-label for other disorders such as the aggressive and 
disruptive disorders (De Hert et al., 2011; Panagiotopoulos et al., 2010; Pringsheim et al., 2011). 
Although the efficacy and benefits of SGAs have been demonstrated in randomized 
controlled trials (RCTs), there is little evidence regarding the long-term safety of using these 
medications in the pediatric population (De Hert et al., 2010; Panagiotopoulos et al., 2010; 
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Pringsheim et al., 2011; Rodday et al., 2015). A systematic review conducted by 
Pringsheim et al. (2011) found evidence confirming the increased risk for both neurological and 
metabolic side effects related to SGA use in children. It has been found that children who receive 
SGAs have a four-fold risk of acquiring diabetes as compared to children who do not receive 
SGAs (NCQA, 2014). Panagiotopoulos et al. (2012) conducted a study to determine the 
prevalence of metabolic syndrome (MetS) in children and adolescents taking SGAs. They found 
the overall prevalence of MetS in children treated with SGAs was 19%. This is a 30-fold higher 
odds ratio than was observed in children with mental health conditions who were never treated 
with an SGA.  
 In response to concerns about the side effects of SGAs, the American Diabetes 
Association (ADA), the American Psychiatric Association (APA), the American Association of 
Clinical Endocrinologists, and the North American Association for the Study of Obesity all 
gathered in 2003 to investigate the relationship between antipsychotic drugs and diabetes. A 
panel of eight experts heard evidence related to the association of antipsychotic use with the 
development of cardiovascular disease (ADA, APA, American Association of Clinical 
Endocrinologists, & North American Association for the Study of Obesity, 2004). In 2004, the 
panel developed a consensus position on how patients taking antipsychotics should be monitored 
and recommended that all patients taking SGAs should have metabolic screening (ADA, APA, 
American Association of Clinical Endocrinologists, & North American Association for the Study 
of Obesity, 2004; Connolly et al., 2015; Morrato et al., 2010; Panagiotopoulos et al., 2010; 
Ronsley et al., 2011). In 2011, the American Academy of Child and Adolescent Psychiatry 
(AACAP) recommended that the metabolic monitoring of children and adolescents taking SGAs 
should follow the recommendations put forth by the ADA and APA whenever feasible. 
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Therefore, due to the risk of weight gain and serious metabolic side effects associated with the 
use of SGAs, it is recommended that children using SGAs have metabolic screening that 
includes measurement of blood pressure (BP), weight, body mass index (BMI), waist 
circumference (WC),  fasting plasma glucose, and fasting lipid profile (De Hert et al., 2011; 
Ghate et al., 2012; Panagiotopoulos et al., 2010; Panagiotopoulos, Ronsley, Kuzeljevic, & 
Davidson, 2012; Pringsheim et al., 2011).   
Despite the importance of monitoring children who are at risk of developing metabolic 
side effects of SGA treatment, a study by Morrato et al. (2010) found that only 31.6% of children 
starting an SGA had a plasma glucose level checked and lipid levels were checked in only 13.4% 
of the children. A study by Connolly et al. (2015) found that between the years of 2003-2011 in a 
population of 52,407 children with a mean age of 13.14 ± 3.72 years who were new users of 
SGAs, around 16% of the population had blood glucose testing per recommended guidelines. 
The National Committee for Quality Assurance (2014) recognizes this failure to obtain 
recommended laboratory monitoring of children and adolescents receiving SGAs as a gap in 
care. 
Several barriers to obtaining recommended metabolic monitoring for children and 
adolescents have been identified. Ronsley et al. (2011) surveyed both community-based and 
hospital-based mental health professionals and found that half of the community-based 
participants reported having low confidence in knowing what metabolic parameters needed to be 
monitored and at what time intervals. A survey completed by Rodday et al. (2015) found that 
psychiatrists who felt the risk of children acquiring metabolic syndrome was low were less likely 
to measure blood pressure and waist circumference.  Another potential barrier to metabolic 
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monitoring may be provider lack of familiarity and agreement with metabolic monitoring 
guidelines (Connolly, Toomey, & Schneeweiss, 2015).   
Evidence suggests that the education and the implementation of metabolic monitoring 
programs can increase rates of monitoring. Ronsley et al. (2012) found that the monitoring rates 
of anthropometric and bloodwork parameters improved after the implementation of a metabolic 
monitoring program that included an educational handbook and training workshops. Gibson et 
al., (2015) found that psychiatric resident knowledge of SGA use in children and adolescents and 
recommended monitoring improved after the implementation of an educational handbook.  
Following recommendations for metabolic monitoring would improve the health and 
wellbeing of children and adolescents who require SGAs for the effective treatment of their 
psychiatric illnesses. Evidence suggests that early screening for metabolic side effects 
contributes to early treatment and the potential to decrease the long-term adverse outcomes from 
treatment with SGAs (Ronsley, Raghuram, Davidson, & Panagiotopoulos, 2011). There are 
pharmacological and non-pharmacological treatments for preventing and managing the weight 
gain experienced by children who use SGAs (Thompson et al., 2011). In addition to healthy 
eating and physical activity, adjunctive treatment with metformin has been found to mitigate the 
weight gain associated with SGA use in children and adolescents (Chovil & Panagiotopoulos, 
2010; Cottingham, Barton, Morrison, Klein, & Sorter, 2006; Pramyothin & Khaodhiar, 2015). 
Problem Statement 
The increase in use of SGAs for the treatment of psychiatric illness in children and 
adolescents may be a result of the perception that SGAs have an improved side-effect panel 
(Panagiotopoulos et al., 2010). While the risk for extrapyramidal symptoms decreases with the 
use of SGAs, these medications can lead to an elevated risk for cardiometabolic disease due to 
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the adverse side effects of weight gain, hyperglycemia, dyslipidemia, hypertension, and type 2 
diabetes (De Hert, Dobbelaere, Sheridan, Cohen, & Correll, 2011; National Committee for 
Quality Assurance, (NCQA), 2014; Nichol et al., 2016; Panagiotopoulos et al., 2010; 
Pringsheim, Lam, Ching, & Patten, 2011; Rodday et al., 2015). Due to the increased use of 
SGAs for children and adolescents with psychiatric illness and the concomitant increase in risk 
for metabolic side effects that these medications can cause, it is imperative that children and 
adolescents using SGAs receive appropriate metabolic monitoring to aid in preventing the 
development of diabetes and future cardiovascular disease (De Hert et al., 2011; Panagiotopoulos 
et al., 2010; Pringsheim et al., 2011).   
 A community-based mental health clinic that provides psychiatric services to children 
and adolescents in the southwestern US has experienced difficulty with obtaining recommended 
metabolic monitoring. A review of records suggests that 80% of children using SGAs have 
received fasting plasma glucose and lipid levels as recommended by current guidelines. Children 
have height, weight, and blood pressure measured at each visit, but, waist circumference is 
usually not measured.  Factors cited by staff as possible barriers to obtaining recommended 
metabolic monitoring are patient non-compliance with obtaining labs, no formal procedure to 
alert providers that monitoring is due, and time constraints during medication review 
appointments.  
The internal and external evidence surrounding this health care issue led to the relevant 
clinical inquiry: In providers who prescribe SGAs to children and adolescents (P) how does 
education on the use of SGAs, the risks of SGAs, and the importance of metabolic monitoring 
for children and adolescents using SGAs (I) compared to no education (C) affect the rates of 
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measuring BP, weight, BMI, waist circumference, fasting plasma glucose, and fasting lipids in 
children and adolescents prescribed SGAs (O) over three months (T)?  
Search Strategy 
 An extensive literature review was performed to address the question of how providing 
education to providers on the risks of weight gain and the adverse metabolic side effects 
associated with SGA use in children and adolescents affects the rates of metabolic monitoring. 
The search strategy included reviews of the Cumulative Index of Nursing and Allied Health 
Literature (CINAHL) (Appendix A), PubMed (Appendix B), PsycINFO (Appendix C), and the 
National Guideline Clearing House (Appendix D). Keywords used to search the databases 
included: second-generation antipsychotic, atypical antipsychotic, metabolic monitoring, and 
waist circumference. Keywords were searched with Boolean connectors: second-generation 
antipsychotic (or) atypical antipsychotic (and) metabolic monitoring (and) waist circumference. 
In addition to database searching, hand-searching of reference lists was used to extract articles.  
Initial Search 
All databases were searched using the same combination of keywords and Boolean 
connectors: second-generation antipsychotic (or) atypical antipsychotic (and) metabolic 
monitoring (and) waist circumference. The initial search yielded 726 results in CINHAL, 25 
results in PubMed, and 2434 results in PsycINFO. Database searches were then limited by year 
of publication, 2005-2017; the English language; and age, child 0-18 years of age. The decision 
to expand the limit for years of publication from 2005 to 2017 reflects the decision to include all 
evidence found after the initiation of metabolic monitoring guidelines in 2004. After the 
application of limits to the search, CINHAL yielded 139 studies, PubMed produced six studies, 
and PsycINFO yielded 229 results.  Hand-searching resulted in one additional article. 
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The National Guideline Clearinghouse was searched using the keywords: Metabolic monitoring 
and second-generation antipsychotics and children. Initial results produced eight guidelines.  
The search was further limited by age: children 2-12 and adolescents 13-18 to capture guidelines 
specific to the pediatric population. After the application of limits, the National Guideline 
Clearinghouse produced a final yield of two guidelines. 
Search Strategy Results 
Studies were selected for further review based on the following inclusion criteria: 
primary research, systematic reviews, or meta-analyses; study population of children less than 18 
years of age; and studies that addressed the metabolic side effects of SGAs in children, barriers 
to metabolic monitoring, recommended guidelines for metabolic monitoring, or proposed 
recommendations for improving metabolic monitoring in children taking SGAs.  
 Two studies were selected that did not meet the inclusion criterion for age. One study 
with a population of subjects greater than 18 years of age was selected as it addressed the cost-
effectiveness of measuring abdominal obesity and fasting blood glucose. Another study, with a 
population age range of 15-25 years of age, was also selected since a portion of the population 
consisted of subjects that met the criterion for age. All articles were published after the year 2011 
except for one article that was published in 2005. This article addressed the sensitivity and 
specificity of waist circumference as a predictor for metabolic syndrome and was considered 
relevant for this review. After critical appraisal of the 27 articles retrieved using these criteria, 
ten were chosen for inclusion in this literature review (Appendix E).  
Critical Appraisal and Synthesis of Evidence 
 Ten studies were retained for this review including: two systematic reviews, level one 
evidence; three quasi-experimental studies (QES), level IV evidence; two surveys, a qualitative 
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study, and a correlational study, all level V evidence; and a cross-sectional retrospective study, 
level III evidence (Appendix E). Level of evidence for each study was determined by using the 
Hierarchy of Evidence presented by Melnyk and Fineout- Overholt (2015). Studies were retained 
if they addressed the following subjects: (a) possible metabolic side effects of SGAs that occur in 
children and adolescents, (b) recommended guidelines for metabolic monitoring, (c) barriers and 
challenges to obtaining recommended metabolic monitoring, (d) or interventions designed to 
improve the rates of metabolic monitoring; thus, the conceptual frameworks, study designs, 
variables, and interventions were heterogeneous and varied according to the purpose of each 
study.  
 The systematic reviews (SR) evaluated RCTs conducted with a population of children 
aged 18 years or younger. One SR, in addition to evaluating RCTs, included open-label and 
prospective cohort studies longer than 12 weeks in duration to assess for the longer-term effects 
of the SGAs. Clinical trials for both studies were evaluated for methodological quality using US 
Preventative Services Task Force criteria.  
 Seven studies were conducted in Canada and received funding from similar sources. The 
seven studies also shared many of the same researchers, some of whom received salary support 
from the Child & Family Research Institute and the Canadian Diabetes Association (Appendix 
E). These studies had heterogenous designs and variables as they addressed various issues of 
SGA use such as identification of adverse effects, recommendation of monitoring guidelines, 
barriers to metabolic monitoring, and interventions to improve metabolic monitoring. The 
sample populations in these studies differed as some study samples were comprised of children 
aged 18 years or younger and other samples were comprised of psychiatric providers who cared 
for children 18 years or younger.  
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Four studies identified obesity, increases in weight, body mass index (BMI), and waist 
circumference (WC) as adverse effects of SGA use and predictors of MetS (Appendix F). The 
sample populations of these studies were mostly homogenous; three of the study samples 
included children aged 18 and younger while one study sample included adults 18 years of age 
and older (Appendix E). Two of these studies calculated the sensitivity, specificity, positive 
predictive value, and positive likelihood ratio of abdominal obesity and WC as predictors of 
MetS and found that abdominal obesity and WC have the highest sensitivity in predicting MetS 
with WC having a higher sensitivity than BMI in predicting MetS in children.  
Three studies evaluated interventions designed to improve the rates of metabolic 
monitoring for children and adolescents receiving SGAs.  The various interventions included 
educational handbooks focused on SGA use and metabolic monitoring in children and 
adolescents, development of guidelines, didactic and interactive seminars, structural changes 
such as the provision of prompts for required monitoring, and provision of the equipment 
necessary to perform required monitoring (Appendix E). The settings in which the interventions 
were implemented were heterogeneous and included hospital-based inpatient units and 
community-based outpatient units. Interventions were provided to psychiatrists, psychiatric 
residents, and mental health professionals who worked with a pediatric population. All three 
studies used a pre-/post-test design. Data were compared using paired t-tests (Appendix E). 
Results in all three studies showed significant improvement in metabolic monitoring rates and 
significant improvement in provider knowledge of SGA use in children after implementation of a 
metabolic monitoring training program or educational handbook.  
 Two surveys explored provider attitudes toward metabolic monitoring and the perceived 
barriers to obtaining recommended monitoring. Descriptive statistics, univariate analysis, and 
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independent t-tests were used to analyze the data (Appendix E). The providers who were 
surveyed cared for pediatric populations in private practice, community, inpatient, and outpatient 
settings. Practice settings and provider attitudes were found to influence patterns of monitoring. 
Outpatient providers had lower confidence with monitoring physical health issues, availability of 
time to complete necessary monitoring, and equipment for performing physical examinations 
(Appendix F). One qualitative study explored the health literacy needs of families with children 
receiving SGAs and found that families felt that they had many questions about SGAs but found 
few resources available to help them.  
 Measurement instruments used across the studies included various types of medical 
equipment, questionnaires, surveys, and audit tools created for chart reviews (Appendix E). One 
study gave detailed information on the type of medical equipment that was used. There was no 
information available on the validity or reliability of the other instruments as they were created 
for the studies by the researchers.   
 Although the studies in this body of work are heterogeneous, when evaluated together, 
they suggest that SGAs increase the risk for metabolic side effects in children and they provide 
evidence that routine metabolic monitoring is required in order to provide quality care to this 
population. The body of work also suggests that barriers to obtaining metabolic monitoring exist 
and that these can be addressed with metabolic monitoring programs and education (Appendix 
E).  
Conclusions from the Evidence 
 High level evidence suggests that SGA use in children and adolescents can lead to 
increased risk for metabolic syndrome and future cardiometabolic disease. Common predictors 
of MetS across studies included, increases in weight, BMI, WC, and abdominal adiposity. 
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Although guidelines and recommendations for metabolic monitoring have been developed that 
include measuring these parameters, routine monitoring of these parameters remains poor for 
children receiving these medications.  
Studies have also shown that the attitudes and beliefs of providers regarding the use of 
SGAs in children can influence the prescribing and monitoring of these medications. Providers 
who believe that the risk for development of MetS in children is low, are less likely to monitor 
for adverse effects. One commonly held belief among providers is that metabolic monitoring is 
not completed due to family non-compliance, however, evidence suggests that families do not 
feel that they have adequate education on these medications, a fact which may contribute to non-
compliance. Education on the use of SGAs and their possible adverse effects for both providers 
and families could increase routine metabolic monitoring.  
In addition, common barriers to obtaining metabolic monitoring have been identified. 
The setting in which treatment occurs can influence which barriers are most likely to impact 
routine metabolic monitoring for children. Metabolic monitoring programs that provide targeted 
interventions specific to the identified barriers in a treatment setting can be successful in 
increasing the rates of metabolic monitoring in children receiving SGAs. 
Purpose and Rationale 
 The purpose of this project was to present an educational intervention that discussed the 
use of SGAs in children, the risks of SGA use, and the current metabolic monitoring 
recommendations for children and adolescents taking SGAs to providers caring for children in a 
community-based mental health clinic with the aim of increasing provider adherence to 
following recommended metabolic monitoring guidelines.  Improving metabolic monitoring for 
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children and adolescents who are taking SGAs is an important aspect of care that can increase 
the wellness of children and help to prevent future cardiometabolic disease.   
EBP Model to Guide Implementation of Evidence 
 The Iowa Model of Evidence-Based Practice was chosen as the framework for designing 
this DNP project (Appendix G).  The model provides a detailed algorithm that begins with 
identifying practice questions or triggers and then guides the practitioner through a decision-
making process for planning a practice change (Dang et al., 2015; Reavy, 2016). There are three 
main decision points: (a) Is this a priority topic? (b) Is there sufficient evidence? and (c) Is this 
change appropriate for adoption into practice? The model then provides feedback and guidance 
on the next step for planning the project based on either a yes or no response to these questions 
(Dang et al., 2015; Reavy, 2016). The Iowa Model of Evidence-Based Practice was chosen for 
this DNP project and guided the process from identification of a practice question to the 
implementation of an evidence-based educational intervention. 
Contribution of Theory to Utility of Evidence 
The Theory of Planned Behavior (Appendix H) was the chosen conceptual model for this 
project. Evidence suggests that provider beliefs and attitudes towards following recommended 
metabolic monitoring guidelines can influence the rates of metabolic screening in children taking 
SGAs. The Theory of Planned Behavior suggests that to predict a person’s intention to do 
something, one needs to know whether the person is (a) in favor of the behavior, his/her attitude; 
(b) how much the person feels social pressure to perform the behavior, the subjective norm; and 
(c) whether the person feels he/she has control over performing the behavior (Francis et al., 
2004). Implementing an educational intervention that affects any of these three variables has the 
potential to change the providers’ attitudes, subjective norms, and perceived behavioral control 
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towards metabolic monitoring and could influence the providers’ intentions to perform metabolic 
monitoring and increase the behavior of metabolic monitoring for children taking SGAs (Francis 
et al., 2004).  
Application of Evidence to Practice 
 Guidelines developed in 2004 recommend routine metabolic monitoring of all people 
taking SGAs. Routine metabolic monitoring includes the measurement of weight, BMI, WC, 
blood pressure (BP), fasting blood glucose, and fasting lipids at baseline, three months, and 12 
months. Although the NCQA (2014) states that ongoing metabolic monitoring for children and 
adolescents taking SGAs is a standard of care, studies suggest that routine metabolic monitoring 
of children taking SGAs does not occur. Evidence suggests, however, that the rates of metabolic 
monitoring increase after providers receive education on SGA use and metabolic monitoring. 
Therefore, an evidence-based project was proposed to provide education on SGA use, risks of 
SGA use, and recommended metabolic monitoring for children to providers in an outpatient 
psychiatric clinic. The stakeholders include the physicians, nurse practitioners (NP), nursing 
staff, NP student, office management staff, children and adolescent patients, and their families.   
Proposed Implications of the Project on Outcomes 
 Implementation of an evidence-based educational program that provides information on 
SGA use in children and adolescents, the risks of SGA use, and the recommended routine 
metabolic monitoring for children has the potential to improve quality outcomes in the outpatient 
psychiatric clinic.  By adhering to recommendations for metabolic monitoring, psychiatric 
providers can improve the quality of care for children and adolescents who are treated with 
SGAs. Routine metabolic monitoring provides a means of identifying metabolic side effects in a 
timely manner making early treatment possible. The early treatment and management of 
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metabolic side effects reduces the long-term costs of treating cardiometabolic disorders by 
reducing the risk that children taking SGAs will develop diabetes or that they will grow into 
adults who have an increased risk for cardiovascular disease (Ghate et al., 2012; NCQA, 2014).  
Project Methods 
This evidence-based project was approved by the Arizona State University Institutional 
Review Board (Appendix I). A recruitment letter describing the project and details of 
participation was presented to all providers of an urban community-based clinic that provides 
psychiatric services for children prior to the pretest questionnaire and the educational 
intervention (Appendix J). A pretest-posttest design was used. An educational intervention 
specifying recommended metabolic monitoring guidelines was presented to providers (Appendix 
K). Providers were asked to complete a pre- and post-education questionnaire that was developed 
using the Francis et al. (2004) manual for constructing a questionnaire based on the theory of 
planned behavior. The questionnaire included a Likert-type scale with 12 items. Responses were 
on a 5-point scale ranging from strongly disagree to strongly agree including a neutral response. 
In addition, the questionnaire included a 14-item self-report of the screening tests ordered by 
providers prior to starting an SGA and at 12 weeks after starting an SGA (Appendix L). This 
instrument does not have established psychometric estimates, however, content validity was 
established by a panel of three experts (Appendix M). The IBM SPSS© Version 24 statistical 
package was used to store, manage, and analyze the data. Descriptive statistics were used to 
describe the sample and outcome variables. Nonparametric statistics were used to analyze the 
outcome variables. A two-tailed test was performed, and the critical value was set at p < 0.05.  
Outcomes/Project Results 
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The sample (N = 6) were healthcare providers of an urban community-based clinic. The 
sample consisted of one (17%) male and five (83%) females. Most of the participants were four 
(67%) nurse practitioners. The remaining participants were medical doctors (n = 2, 33%). The 
average age of the participants was 47.5 (SD = 10.25) years and the ages ranged from 35-63 
years in age. The average number of years in practice for the participants was 11.17 (SD = 
15.08) with the range of years in practice from 1- 41 years in practice.  
Descriptive statistics were used to describe the pre-education and post-education means 
of the four variables of the theory of planned behavior (Table 1). A Wilcoxon test examined the 
results of the pre-education and post-education mean scores for each of the four variables of the 
theory of planned behavior (Table 1). No significant differences were found in the results for any 
variable. 
Table 1 
Wilcoxon Test Results for Theory of Planned Behavior Variables 
 
Variable  
Pre-intervention  
M (SD) 
Post-intervention 
M (SD) 
  
Z 
 
p  
Intention 
 
13.33 (1.21) 13 (1.55) -.55 .581 
Attitude 
 
16.67 (3.08) 17.25 (1.50) .00 1.000 
Subjective Norm 
 
15.60 (4.72) 13.8 (3.77) .37 .713 
Perceived Behavioral 
Control 
Note (N=6) 
12.67 (1.97) 12.67 (2.58)   -.27 .785 
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A McNemar test determined that there was no significant difference in provider ordering 
of metabolic screening pre- and post-intervention (Table 2). The McNemar test was not 
performed on the variables of pre- and post-intervention BP, weight, height, and BMI as the 
variables for both pre- and post- education had the same value and were not dichotomous.  
Table 2 
Percentage of Providers Who Ordered Screening Tests Pre- and Post-Intervention (N = 6) 
Screening Test Pre- education Post-education 
Baseline WC 0% 40% 
Baseline FPG 100% 83%  
Baseline FL 100% 83%  
12-week WC 0% 20%  
12-week FPG 20% 67%  
12-week FL 20% 67%  
Note. (N =6); WC = waist circumference; FPG = fasting plasma glucose; FL = fasting lipids. 
Discussion 
Project results found no significant differences in the average scores of the four variables 
of the theory of planned behavior from pre- to post-intervention; however, there was an increase 
in the average score for provider attitude toward following guidelines. The average scores for 
provider subjective norms and perceived behavioral control toward following guidelines were 
lower than the average provider attitude score. There was no difference in the proportion of 
providers ordering recommended screening tests from pre- to post-intervention, but, after the 
intervention, there was (a) an increase in the proportion of providers who measured waist 
circumference before starting an SGA and at 12 weeks after starting an SGA and (b) an increase 
in the proportion of providers who ordered lab tests at 12 weeks after starting an SGA. 
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Relation of Findings to Other Studies  
These results are consistent with findings from Gibson et al. (2015) who found that 
psychiatric resident knowledge of SGA use in children and adolescents and knowledge of 
recommended monitoring improved after the implementation of an educational handbook.  
Thompson et al. (2011) and Ronsley et al. (2012) also reported finding that metabolic monitoring 
rates improved significantly with the implementation of metabolic monitoring programs that 
included education. Rodday et al. (2015) found that providers who believed that the risk for 
MetS was low did not measure WC and providers with more years in practice did not order FPG 
and FL due to beliefs that patients are noncompliant. Educating providers with evidence that 
SGAs increase the risk for elevated FPG, MetS, and future cardiometabolic disease may serve to 
change the attitudes and beliefs of these providers toward the value of routine monitoring. The 
increase in attitude toward following guidelines and the resulting increase in metabolic 
monitoring behaviors seen in this project is consistent with the theory of planned behavior that 
states that if there is a change in attitude, subjective norms, or perceived behavioral control, 
intention to perform a behavior and the actual performance of the behavior will change as well.  
Impact of the Project 
This evidence-based project presented providers with education on the current 
recommended metabolic monitoring guidelines and the importance of measuring WC in children 
younger than 18. The impact of this education on provider knowledge can be seen in the 
resulting increase in the proportion of providers who started (a) to measure WC when starting an 
SGAs and at 12 weeks after starting an SGA and (b) to order FPG and FL at 12 weeks after 
starting an SGA. While these results were not statistically significant, clinically, any 
improvement in metabolic monitoring serves to improve the safety and quality of care for 
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children who are taking these medications. Early identification of metabolic side effects and 
treatment of side effects through coordination with primary care providers mitigates the risk for 
future cardiometabolic disease.  
Sustaining the Improvement 
 Fleiszer, Semenic, Ritchie, Richer, and Denis (2016) who studied the long-term 
sustainability of nursing best practice guidelines suggest that sustaining guideline adherence 
depends on three elements; benefits, routinization, and development. The study also found that 
one of the factors that sustains implementation is accountability (Fleiszer, 2016). To sustain the 
improvement in following metabolic monitoring guidelines that resulted from this evidence-
based project, it will be important to (a) continue to reinforce the benefits of following guidelines 
for both providers and patients, (b) develop a culture of accountability toward following 
metabolic monitoring guidelines to increase provider subjective norms, (c) develop workflows to 
establish a metabolic monitoring routine in the clinic and increase the perceived behavioral 
control of providers, and (d) continue to monitor research for updates on guideline 
recommendations (Fleiszer, 2016). Strong leadership that supports the goal of improving 
metabolic monitoring for children taking SGAs, project champions, and alignment of the goal of 
improving metabolic monitoring with organizational values will also help to sustain this 
evidence-based project (Douglas, Button, & Casey, 2014). 
Limitations 
The main limitations of this project were the small sample size and the use of self-reports 
to measure the percentage of providers who ordered specific screening tests.  
Conclusion 
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 Using SGAs to treat children and adolescents with behavioral health diagnoses is 
becoming more common. These medications increase a child’s risk for future cardiometabolic 
disease. It is important to routinely monitor children for the cardiometabolic side effects of SGAs 
so that early identification and treatment can occur. The purpose of this evidence-based project 
was to improve metabolic monitoring for children taking SGAs by implementing an educational 
intervention that discussed the use and risks of SGAs with children and the attendant 
recommended metabolic monitoring guidelines. The theory of planning behavior was used as the 
conceptual framework for his project. While the results of the project were not statistically 
significant, there was some improvement in following recommended guidelines. Based on the 
theory of planned behavior and evidence on sustaining guidelines, it is recommended that future 
interventions aimed at improving and sustaining metabolic monitoring focus on improving 
provider subjective norms and perceived behavioral control.  
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Table 1 
Evaluation Table 
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Chovil et al. (2010). 
Engaging families in research 
to determine health literacy 
needs related to the use of 
second-generation 
antipsychotics in children and 
adolescents. 
 
Funding: Lawson Foundation, 
CFRI, and CDA. 
 
No COI or biases recognized 
 
Canada 
. 
Inferred 
Health 
Belief 
Model  
 
Design: EQS 
 
Purpose: To 
engage parents 
and caregivers in 
research that 
explores their 
health literacy 
needs regarding 
the use of SGAs 
in children and 
youths.  
N= 14 
 
Convenience 
sample  
 
Data collected 
from two focus 
groups, n=7 
parents/caregivers
.  
 
Setting: 
Community 
center 
 
Inclusion 
criteria: 
Parent/caregiver 
of a child or 
adolescent with a 
MH dx and 
Health literacy 
needs of 
families with 
children taking 
SGAs 
Focus groups  Transcripts 
of focus 
groups were 
reviewed 
until no 
further 
themes were 
derived. 
Participants 
were asked to 
review the 
document for 
accuracy and 
completeness
. 
Themes:  
1. Families’ 
experience in 
accessing 
information about 
medicines. 
2. 
Parents/caregiver 
recommendations 
on provision of 
information to 
families.   
3. Healthy eating: 
barriers and 
strategies. 
4.Physical 
activity: barriers 
and strategies.  
5. 
Recommendation
s for resources on 
Level V 
 
Strengths: 
validation of 
data by 
informants, 
transferability 
and 
confirmability. 
 
Weaknesses: 
little 
information on 
data collection 
and analysis. 
 
Conclusions: 
there is value 
in including 
the “family” 
voice when 
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current or past 
use of an SGA. 
healthy active 
living.  
developing 
educational 
strategies 
related to 
medications 
such as SGAs 
  
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Gibson et al. (2015).  
Effectiveness of an educational 
handbook in improving 
psychiatry resident knowledge 
of second-generation 
antipsychotics.  
 
Funding: One author has 
received funding support from 
the CFRI and CDA. 
 
No COI declared by authors.  
  
Bias: Lack of a control group. 
One author receives salary 
support from Canucks for Kids 
Fund, CIHR, and the CFRI 
Clinical Research Capacity 
Building Award.  
 
Canada 
 
 
Inferred 
Bandura’s 
Self-
Efficacy. 
Design: QED 
Prospective pre-
/post-analysis 
study 
 
Purpose: To 
determine 
whether the 
introduction of 
an educational 
handbook 
improves 
psychiatry 
resident 
knowledge of 
SGAs. 
N= 56 residents 
who completed 
baseline 
questionnaire 
 
n= 32 psychiatry 
residents who 
completed both 
baseline and post-
intervention 
questionnaires.  
 
n= 20 female 
n=29 post 
graduate year 3 
n= 3 post 
graduate year 4 
and 5 
 
Setting: BCCH 
IV- 
educational 
handbook 
 
DV1: 
knowledge of 
properties that 
distinguish 
SGAs from 
typical 
antipsychotic 
DV2: 
knowledge of 
on-label 
indications for 
SGA use in 
pediatrics in 
Canada. 
DV3: 
Knowledge of 
off-label 
indications for 
SGA use in 
pediatrics in 
Questionnaire  Paired t -tests Significant 
improvement in 
mean scores from 
18.4 ± 4.23 at 
pre-test to 21.2 ± 
3.28 at post-test. 
P= 0.001. Effect 
size 0.74 
Level: III 
 
Strengths: 
significant 
results 
consistent with 
findings from 
previous pilot 
studies. 
Adequate 
sample size. 
 
Weaknesses: 
Lack of a 
control group. 
No repeat 
questionnaire 
to assess 
retention of 
information 
months after 
the 
intervention. 
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Canada. 
DV4: 
Knowledge of 
potential SEs 
of SGAs in 
children and 
adolescents. 
DV5: 
knowledge of 
pertinent 
information 
from patient 
history prior to 
starting an 
SGA.  
DV6: 
knowledge of 
specific 
aspects of PE 
that are 
required prior 
to starting and 
SGA and at f/u 
visits. 
DV7: 
knowledge of 
baseline and 
f/u labs to 
order. 
  
 
Conclusions: 
results suggest 
that the 
implementatio
n of a 
handbook can 
improve 
resident 
knowledge of 
related to SGA 
use in children 
over the short-
term.   
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
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Findings Decision for 
use 
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Panagiotopoulos et al. (2012). 
Waist circumference is a 
sensitive screening tool for 
assessment of metabolic 
syndrome risk in children 
treated with second-generation 
antipsychotics.  
 
Funding:  Lawson Foundation 
and CDA.  
 
No COI declared by authors. 
 
Bias: Selection bias. One 
authors receives salary support 
from CFRI and the Canadian 
Diabetes Association Clinician 
Scientist Awards. 
 
Canada 
Physiologic 
Theory 
 
Design: CSRS 
 
Purpose: To 
compare the 
prevalence of 
MetS and its 
components in 
SGA-treated and 
SGA-naïve 
children. To 
explore the 
utility of clinical 
markers such as 
WC and BMI for 
as screening 
tools for MetS. 
N= 334 
n= 117 SGA- 
treated 
n= 217 SGA-
naïve 
 
Inclusions: 
Children < than 
age 18 admitted 
to Child and 
Adolescent 
Psychiatric 
Emergency unit 
between 1/1/2008 
and 2/5/2010.  
 
Exclusions: 
eating disorder, 
pre-existing T1D 
or T2D, pre-
existing 
endocrine 
disorder, 
receiving 
concomitant 
glucocorticoid 
medication, 
receiving 
intermittent 
treatment with an 
SGA. 
 
Setting: IP 
IV1: SGA 
 
DV1: 
prevalence of 
MetS. 
DV2: utility of 
clinical 
markers such 
as WC. 
 
 
. 
Tronix Scale,  
Seca 240 
stadiometer, 
non-elastic 
flexible 
measuring 
tape, 
Dinamap, lab 
results.  
2-tailed 
independent 
samples t -
tests and 
Mann-
Whitney U 
tests.  
 Logistic 
regression to 
assess 
predictors of 
MetS 
Data also 
used to 
analyze 
uptake of an 
MMP; 
characteristic
s of SGA-
treated 
children with 
MetS; 
sensitivity, 
specificity, 
PPVs, and 
Positive 
likelihood 
ratios for the 
components 
of MetS; and 
obesity 
predictors of 
MetS 
WC ≥ 90th 
percentile had the 
highest 
sensitivity, 
92.9%, of 
correctly 
identifying 13 of 
14 patients with 
MetS. 
Specificity-
76.5%, 
PPV448%, 
Positive 
likelihood ratio = 
3.9 
Level III 
 
Strengths: 
prospective 
study with 
comparison of 
SGA treated 
children to an 
untreated 
group. 
Detailed 
measurement 
procedures.  
 
Weaknesses: 
cross-sectional 
design, groups 
were not 
evenly 
matched for 
age or sex. 
Limited 
number of 
subjects 
identified with 
MetS.  
 
Conclusions: 
WC is a 
simple and 
sensitive 
screening tool 
for 
determining 
METABLIC MONITORING IN CHILDREN              35 
 
AE- adverse effect, AMA- American Medical Association, BCCH- British Columbia Children’s Hospital, BMI- body mass index, BP- blood pressure, BS- blood sugar, CDA- 
Canadian Diabetes Association, CFRI- Child & Family Research Institute, CHOL- cholesterol, CIHR- Canadian Institute of Health Research, CMHT- community mental health 
team, COI- conflict of interest, CSRS- cross-sectional retrospective study, CTSI- Clinical and Translational Service Institute, CYMHT- Child and Youth Mental Health Team, 
DB- double blind, DV- dependent variable, dx- diagnosis, ECG- electrocardiogram, EPS- extrapyramidal symptoms, EQS- exploratory qualitative study, FBG- fasting blood 
glucose, f/u- follow-up, H- height, HDL-C- high-density lipoprotein cholesterol, HR- heart rate, IV- independent variable, IP- inpatient, LDL-C- low-density lipoprotein 
cholesterol, LFT- liver function tests, MA- meta-analysis, MetS- metabolic syndrome, MH- mental health, MM- metabolic monitoring, MMP- metabolic monitoring program, 
MMTP- metabolic monitoring training program, OP- outpatient, PC- primary care, PCS- prospective cohort study, PE- physical exam, PPV- positive predictive value, QED-
quasi-experimental design, QES- quasi-experimental study, RCR- retrospective chart review, RCS- retrospective cohort study, RCT- randomized controlled trial, SE- side effect, 
SGA- second-generation antipsychotic, SR- systematic review, T1D- type 1 diabetes, T2D- type 2 diabetes, TG- triglycerides, WC-waist circumference, W-weight 
 
MetS in SGA 
treated 
Children.  
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Pringsheim et al. (2011).  
Metabolic and neurological 
complications of second-
generation antipsychotic use in 
children. 
 
Funding: CIHR. 
 
No COI or biases recognized 
 
Canada 
 
 
Physiologic 
Theory 
Design: SR and 
MA 
 
Purpose: To 
assess for the 
specific 
metabolic and 
neurological AE 
associated with 
the use of SGAs 
in children 
 
N= 35 RCTs 
n=19 RCTs for 
risperidone 
section 
n= 7 RCTs for 
olanzapine 
section 
n= 4 RCTs for 
quetiapine section 
n= 5 RCTs for 
aripiprazole 
section 
n=3 RCTs for 
clozapine section 
n=1 RCT for 
ziprasidone 
section 
IV1: 
risperidone 
IV2: 
olanzapine 
IV3: 
quetiapine 
IV4: 
aripiprazole 
IV5: clozapine 
IV6: 
ziprasidone 
 
DV1: W 
DV2: weight 
gain >7%of 
baseline 
bodyweight 
Physical 
examination, 
rating scales, 
and lab tests.  
ORs with 
95% CI, 
I2 index, 
meta-analysis 
for each 
medication 
individually.  
Separate results 
for each 
medication. Risk 
of metabolic 
adverse effects 
greatest with 
olanzapine 
followed by 
clozapine and 
quetiapine. 
Metabolic risks 
appear lower for 
risperidone and 
aripiprazole. Data 
on ziprasidone is 
scarce.  
Level 1 
 
Strengths: 
overall trial 
quality high 
with 32 of 35 
studies 
receiving a 
rating of good 
or fair by 
USPSTF 
criteria  
 
Weaknesses: 
short duration 
of the RCTs, 
some 
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Inclusions: DB 
RCT of SGA 
medications vs 
placebo or an 
active comparator 
in a pediatric 
population 
(children up to 
age 18) with a 
MH dx, or an 
RCT that 
included a 
separate analysis 
for pediatric 
participants if the 
study included 
adults.  
 
DV3: WC 
DV4: BMI 
DV5: BP 
DV6: HR 
DV7: EPS 
DV8: ECG 
DV9: Fasting 
total chol, 
LDL-C, HDL-
C, TG 
DV10: BS 
DV11: 
prolactin 
DV12: LFT 
DV13: TSH, 
T4 
Risperdal trials 
did not include 
metabolic lab 
testing,    
 
Conclusions: 
There is good 
evidence to 
support the 
existence of 
both metabolic 
and 
neurological 
adverse effects 
in children 
treated with 
SGAs 
therefore 
proper 
attention and 
vigilance to 
potential 
metabolic and 
neurologic 
adverse effects 
is necessary. 
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Pringsheim et al. (2011).  
Evidence-based 
recommendations for 
monitoring safety of second-
generation antipsychotics in 
children and youth.  
 
Funding: CIHR.  
 
No COI declared by authors  
 
Bias: One author receives 
salary support from the CFRI 
and CDA. 
 
Canada 
Physiologic 
Theory 
Design: SR 
 
Purpose: To 
synthesize the 
evidence for 
specific 
metabolic and 
neurological SEs 
associated with 
the use of SGAs 
in children and 
provide 
recommendation
s for monitoring 
SEs 
 
 
n= 57 articles for 
risperidone  
n= 25 articles for 
olanzapine 
n= 17 articles for 
quetiapine 
n= 8 articles for 
aripiprazole 
n= 8 articles for 
clozapine 
n= 5 articles for 
ziprasidone 
 
 
Inclusions: DB 
RCT of SGA 
medications 
performed 
specifically in a 
pediatric 
population with 
MH dx. Open-
label and PCSs 
longer than 12 
weeks.  
When data was 
not available 
from the above, 
RCSs, case series, 
case reports, and 
drug surveillance 
programs were 
searched. 
IV1: 
risperidone 
IV2: 
olanzapine 
IV3: 
quetiapine 
IV4: 
aripiprazole 
IV5: clozapine 
IV6: 
ziprasidone 
 
DV1: weight 
gain 
DV2: prolactin 
levels 
DV3: EPS 
DV4: BMI 
DV5: BS 
DV6: TG 
DV7: Total 
chol 
DV8: LFT 
DV9: WC 
DV10: Insulin 
DV11: TSH, 
T4 
DV12: LDL-
C, HDL-C 
 
USPSTF 
criteria to eval.  
methodologica
l 
Quality. Trials 
rated using 
GRADE  
Meta-
analysis 
Evidence-based 
guidelines for 
monitoring SGA 
safety developed.  
Level I 
 
Strengths: 
guidelines 
were based on 
current 
evidence that 
examined the 
metabolic and 
neurological 
adverse effects 
of SGA 
medications.  
 Limitations: 
unable to 
develop 
guidelines for 
monitoring 
beyond one 
year due to 
lack of long-
term studies.  
 
Conclusions: 
appropriate 
monitoring 
procedures for 
adverse effects 
will improve 
the quality of 
care for 
children 
treated with 
SGAs.  
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Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Rodday et al. (2015). 
Child and adolescent 
psychiatrists’ reported 
monitoring behaviors for 
second-generation 
antipsychotics. 
 
Funding: Tufts CTSI  
 
No COI declared by authors. 
 
Bias: Low response rate with 
possible sampling bias. Two 
authors with multiple 
funding/grant disclosures.   
 
USA 
 
Inferred 
Bandura’s 
Self-
Efficacy. 
Design: Survey 
Research 
 
 
Purpose: To 
explore 
monitoring 
practices and 
factors that may 
be associated 
with monitoring 
for children 
prescribed 
SGAs. 
 
N= 6156 child 
and adolescent 
psychiatrists 
identified from an 
AMA mailing list 
in 2012 
 
n= 1600 
randomly selected  
 
n= 362 
respondents 
 
n= 334 final 
sample who met 
eligibility criteria.  
 
Inclusions: 
provided care for 
children 3-18 
years of age,  
prescribed SGAs 
to children 3-18 
years of age, 
specialized in 
child and 
adolescent 
psychiatry 
 
Exclusions: 
Retired 
IV1: 
psychiatrist 
characteristics 
IV2: 
psychiatrist 
attitudes and 
use of SGAs 
IV3: practice 
characteristics 
 
DV– routine 
monitoring of 
the following 
at least once 
per year: 
patient history, 
H, W, BP, 
WC, lipid & 
glucose levels, 
ECG 
Survey 
developed by 
the study 
investigators  
Descriptive 
statistics, X2 
or Fisher 
exact test, 
Anova.  
66% of 
respondents 
reported routinely 
monitoring 
history, 92% 
routinely 
monitored H & 
W, 76% routinely 
monitored BP, 
23% routinely 
monitored WC, 
81% routinely 
monitored lipid 
and FPG, 12% 
routinely 
monitored ECG. 
 
 
 
 
 
Level V 
 
Strengths:  
use of a 
national 
sample with 
random 
selection 
 
Weaknesses: 
low response 
rate with 
inability to 
compare 
respondents 
with non-
respondents. 
Inability to 
compare 
reported 
behaviors with 
actual 
performance.  
 
Conclusion: 
metabolic 
monitoring 
patterns are 
inconsistent 
for children 
prescribed 
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psychiatrists, 
psychiatrists not 
based in the USA, 
residents or 
fellows.  
 
Setting: Private 
practice, CMHC, 
IP, OP 
SGAs. 
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Ronsley et al. (2011).  
Barriers and facilitators to 
implementation of a metabolic 
monitoring protocol in hospital 
and community settings for 
second-generation 
antipsychotic-treated youth. 
 
Funding: Lawson Foundation 
and CDA.  
 
No COI disclosed by authors, 
 
Bias:  
Sampling bias and Selection 
bias. Two authors supported by 
CFRI, CDA, and summer 
studentship award from CFRI. 
  
Canada 
Inferred 
Bandura’s 
Self-
Efficacy 
Design: Survey 
research,  
online 
questionnaire 
 
Purpose: To 
assess barriers to 
MM in SGA 
treated-youth. 
To propose an 
MMP and 
implementation 
strategies.  
N= 161 MH 
professionals 
working at either 
CMHT or BCCH 
n= 26 CMHT 
respondents 
n= 44 BCCH 
respondents 
 
Inclusions: 
counselors, 
psychologists, 
social workers, 
nurses, physicians 
who work with 
youth 
 
Setting: IP, OP 
Themes:  
1. Physical 
health care 
2. Confidence 
with 
monitoring 
physical health 
3. Interface 
with PC. 
4. Practical 
issues faced by 
team.  
5. Strategies 
for 
implementatio
n 
 
  
Questionnaire, 
5-point Likert 
Scale  
Descriptive 
analysis, 
independent t 
-test 
1.Monitoring 
physical health is 
responsibility of 
MH professional- 
CMHT, 83.3%, 
BCCH, 90.9% 
2. Knowing what 
should be 
monitored -
CMHT, 3.1±1.36 
BCCH, 3.9± 
0.98. confidence 
with interpreting 
results- CMHT, 
2.0±1.34, BCCH, 
3.6±1.19 based 
on Likert scale  
Level V 
 
Strengths:  
Response rate 
is consistent 
with previous 
surveys in 
similar 
populations.  
 
 
Weaknesses: 
Larger number 
of BCCH than 
CMHT. 
Reflect the 
opinions of 
urban 
professionals 
only.  
 
Conclusion: 
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There are more 
barriers to 
implementing 
a MMP in the 
community vs 
a hospital-
based setting. 
There is lower 
confidence in 
in performing 
MM in the 
community 
and more 
practical issues 
such as lack of 
time and 
access to exam 
rooms.  
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Ronsley et al. (2012).  
Metabolic monitoring training 
program implementation in the 
community setting was 
associated with improved 
monitoring in second-
generation antipsychotic-
treated children. 
 
Funding: Lawson Foundation 
and Provincial Health Services 
Authority.  
 
Inferred 
Cognitive 
Learning 
Theory 
Design: QED, 
pre-/post-test/ 
RCS 
 
Purpose: To 
determine if 
implementation 
of a MMTP 
improves 
monitoring and 
prescription rates 
of SGAs in 
children 
N= 2376 children 
(mean age 11.8 
years, SD= 4.81, 
range= 1.86-
18.34) seen at 
CYMHTs 
 
n= 1114 children 
seen at CYMHTs 
9/1/2007-
12/31/2008 (pre-
MMTP) 
 
IV- MMTP 
 
DV1: 
percentage of 
SGA- treated 
children with 
MM 
completed 
before and 
after MMTP 
DV2: 
prescription 
changes pre- 
review of 
paper charts 
and electronic 
records.  
Descriptive 
Statistics, 
Chi-square  
Differences 
between all pre- 
and post-MMTP 
were significant 
for all 
anthropometric 
measurements 
and blood work 
parameters, (p < 
0.01). 
 
Level IV 
 
Strengths: 
data was 
collected from 
paper charts, 
electronic 
record and 
CYMHT staff 
to gather all 
info. 
 
Weaknesses: 
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No conflict of interest 
disclosed by authors. 
 
Bias: No control group. 
Information bias. One author 
supported by CDA and CFRI. 
 
Canada 
prescribed 
SGAs. 
n= 1262 children 
seen at CYMHTs 
1/1/2009-
4/30/2010 (post- 
MMTP) 
 
N= 253 Subgroup 
SGA-treated 
children (mean 
age 14.5 years, 
SD= 3.71, range= 
5.17-18.34 years) 
 
n= 172 subgroup 
pre-MMTP 
n= 81 subgroup 
post-MMTP 
 
Setting: urban 
community-based 
 
 
 
and post-
MMTP in all 
children 
DV3: 
prescription 
changes of 
concomitant 
medications in 
pre- and post-
MMTP in 
SGA-treated 
children 
no control 
group 
 
Conclusion: 
implementatio
n of an MMTP 
was associated 
with improved 
MM 
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Straker et al. (2005). 
Cost-effective screening for the 
metabolic syndrome in patients 
treated with second-generation 
antipsychotic medications.  
 
Funding: Zucker Hillside 
Hospital Intervention research, 
Physiologica
l Theory 
 
Design: Cross-
sectional, 
descriptive 
correlational 
prevalence study 
 
Purpose: To 
assess the 
N= 89 (mean age 
= 39.8 years, SD= 
15.3, range= 18-
78, 50.6% male, 
51.7% Caucasian) 
consecutively 
admitted psych 
patients between 
IV1- SGA 
IV2: elevated 
FBG or history 
T1D, T2D 
IV3: high BP 
IV4: fasting 
TG 
IV5: LDL-C, 
BP, WC, FBG, 
and Lipid 
levels.  
Chi-square 
tests, 
ANOVA, 
sensitivity & 
specificity, 
PPV, and 
positive 
likelihood 
Twenty-six 
participants 
(29.2%) met 
criteria for MetS. 
MetS was 
significantly 
associated with 
older age 
Level V 
 
Strengths: 
largest study to 
date assessing 
the 
relationship 
between 
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Center for schizophrenia; 
National Institute of Mental 
Health grant; and Stanley 
Research Fellowship Grant.  
 
No COI noted by authors 
 
Bias: Lack of a control without 
SGA use. Two authors have 
disclosed association to 
multiple pharmaceutical 
companies.  
 
USA 
prevalence of 
MetS in patients 
treated with 
SGA.   
To determine the 
most clinically 
useful and cost-
effective method 
for MetS 
screening. 
August and 
November 2002 
with or without 
MetS. 
 
Inclusion: 
treatment with at 
least one SGA: 
clozapine, 
olanzapine, 
quetiapine, 
risperidone, and 
ziprasidone.  
 
Setting- IP 
 
HDL-C 
IV6: 
abdominal 
obesity 
IV7: 
Abdominal 
obesity and/or 
elevated FBG 
IV8: 
abdominal 
obesity and/or 
high BP 
 
 
DV1: MetS 
DV2: 
predictive 
value of 
individual 
criteria on 
MetS 
ratio. 
P = 0.05  
(X2=6.23, df =1, 
p<0.02), and 
higher BMI. 
MetS was not 
significantly 
associated with 
SGA use. 
Abdominal 
obesity had the 
highest sensitivity 
(92%), elevated 
FBG had the 
highest 
specificity 
(95.2%).  
antipsychotic 
use and MetS 
 
 
Weaknesses: 
cross-sectional 
design, small 
sample, lack of 
a control 
group. 
 
Conclusion: 
The 
measurement 
of WC and 
FBG are 
simple and 
cost effective 
screening 
methods for 
MetS. 
Citation Conceptual 
Framework 
Design/ Method Sample/ Setting Major 
Variables & 
Definitions 
Measurement Analysis 
 
Findings Decision for 
use 
Thompson et al. (2011). 
Targeted intervention to 
improve monitoring of 
antipsychotic-induced weight 
gain and metabolic disturbance 
in first episode psychosis. 
 
Funding: Melbourne 
University Knowledge 
Transfer Grant and Colonial 
Inferred 
Cognitive 
Learning 
Theory.  
Bandura’s 
self-
Efficacy. 
 
 
Design: QES, 
Pre-/Post-
intervention 
analysis  
 
Purpose: To 
determine if a 
targeted 
intervention 
could improve 
n= 106 pre-
intervention 
(mean age 21.1 
years, SD= 2.7).  
n= 86 post-
intervention 
(mean age 20.2 
years, SD= 2.5). 
 
Inclusions:  
IV: targeted 
intervention 
including; 
provision of 
monitoring 
equipment, 
interactive 
education, 
reminders and 
prompts within 
Predesigned 
audit form. 
t-test, 
Pearson’s 
and Mantel-
Haenszel chi. 
Minimum 
metabolic 
screening was 
completed within 
6 months of 
starting an 
antipsychotic on 
22% (n= 24) of 
patients pre-
intervention, 
Level IV 
 
Strengths: 
detailed 
description of 
the 
intervention 
 
Weaknesses: 
non-
METABLIC MONITORING IN CHILDREN              43 
 
AE- adverse effect, AMA- American Medical Association, BCCH- British Columbia Children’s Hospital, BMI- body mass index, BP- blood pressure, BS- blood sugar, CDA- 
Canadian Diabetes Association, CFRI- Child & Family Research Institute, CHOL- cholesterol, CIHR- Canadian Institute of Health Research, CMHT- community mental health 
team, COI- conflict of interest, CSRS- cross-sectional retrospective study, CTSI- Clinical and Translational Service Institute, CYMHT- Child and Youth Mental Health Team, 
DB- double blind, DV- dependent variable, dx- diagnosis, ECG- electrocardiogram, EPS- extrapyramidal symptoms, EQS- exploratory qualitative study, FBG- fasting blood 
glucose, f/u- follow-up, H- height, HDL-C- high-density lipoprotein cholesterol, HR- heart rate, IV- independent variable, IP- inpatient, LDL-C- low-density lipoprotein 
cholesterol, LFT- liver function tests, MA- meta-analysis, MetS- metabolic syndrome, MH- mental health, MM- metabolic monitoring, MMP- metabolic monitoring program, 
MMTP- metabolic monitoring training program, OP- outpatient, PC- primary care, PCS- prospective cohort study, PE- physical exam, PPV- positive predictive value, QED-
quasi-experimental design, QES- quasi-experimental study, RCR- retrospective chart review, RCS- retrospective cohort study, RCT- randomized controlled trial, SE- side effect, 
SGA- second-generation antipsychotic, SR- systematic review, T1D- type 1 diabetes, T2D- type 2 diabetes, TG- triglycerides, WC-waist circumference, W-weight 
 
Foundation.  
 
No COI noted by authors 
 
Bias: Information bias. 
Selection bias. Sampling bias. 
Three authors have disclosed 
funding/grants/awards/honorari
a from fellowships and 
multiple pharmaceutical 
companies. 
 
Australia 
levels of 
monitoring in a 
first episode 
psychosis clinic.  
For admission 
into program, pts 
must have 
psychotic D/O 
and have not 
previously 
received more 
than 6 months of 
treatment.  
 Pre-intervention 
audit: files of all 
patients admitted 
consecutively for 
the first time 
between 1/1/2006 
and 6/30/2006.  
Post-intervention 
audit: files of all 
patients admitted 
consecutively 
between 9/1/2008 
and 2/28/2009.  
Must be 
prescribed 
antipsychotics. 
 
Setting: Early 
Psychosis 
Prevention and 
Intervention 
Centre that serves 
clients 15-25 
years of age. 
team structure 
to entire cohort 
of clinicians 
working at the 
clinic 
 DV1: 
guideline 
concordant 
monitoring 
DV2: 
minimum MM 
DV3: 
Minimum 
metabolic 
screening.  
significant 
improvement was 
found post-
intervention, 
81.4% (n=70) 
(Mantel- 
Haenszel chi = 
8.171, p <0.001.  
The rate of 
minimum MM 
improved 
significantly from 
1.7% (n=2) to 
39.5% 
(n=34) post- 
intervention 
(Mantel-Haenszel 
chi = 6.897, p < 
0.001. 
randomized, 
acknowledged 
turnover of 
staff, the 
clinicians 
audited were 
not the same 
for each audit, 
tests may have 
been ordered 
by physicians 
from another 
service, and 
the post- 
intervention 
sample was 
statistically 
younger than 
the follow-up 
sample.  
 
Conclusion: 
using a 
targeted 
implementatio
n strategy 
substantially 
improved 
routine 
screening and 
monitoring  
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AE- adverse effect, AMA- American Medical Association, BCCH- British Columbia Children’s Hospital, BMI- body mass index, BP- blood pressure, BS- blood sugar, CDA- 
Canadian Diabetes Association, CFRI- Child & Family Research Institute, CHOL- cholesterol, CIHR- Canadian Institute of Health Research, CMHT- community mental health 
team, COI- conflict of interest, CSRS- cross-sectional retrospective study, CTSI- Clinical and Translational Service Institute, CYMHT- Child and Youth Mental Health Team, 
DB- double blind, DV- dependent variable, dx- diagnosis, ECG- electrocardiogram, EPS- extrapyramidal symptoms, EQS- exploratory qualitative study, FBG- fasting blood 
glucose, f/u- follow-up, H- height, HDL-C- high-density lipoprotein cholesterol, HR- heart rate, IV- independent variable, IP- inpatient, LDL-C- low-density lipoprotein 
cholesterol, LFT- liver function tests, MA- meta-analysis, MetS- metabolic syndrome, MH- mental health, MM- metabolic monitoring, MMP- metabolic monitoring program, 
MMTP- metabolic monitoring training program, OP- outpatient, PC- primary care, PCS- prospective cohort study, PE- physical exam, PPV- positive predictive value, QED-
quasi-experimental design, QES- quasi-experimental study, RCR- retrospective chart review, RCS- retrospective cohort study, RCT- randomized controlled trial, SE- side effect, 
SGA- second-generation antipsychotic, SR- systematic review, T1D- type 1 diabetes, T2D- type 2 diabetes, TG- triglycerides, WC-waist circumference, W-weight 
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ABD- abdominal, BMI- body mass index, CSRS- cross-sectional retrospective study, DV- dependent variable, ED- educational, FBG- fasting blood glucose, EQS- exploratory 
qualitative study, HB- handbook, HL- health literacy, IP- inpatient, IV- independent variable, KD- knowledge deficit, LOE- level of evidence, MA- meta-analysis, MetS- 
metabolic syndrome, MM- metabolic monitoring, MMTP- metabolic monitoring training program, NC- non-compliance, OP- outpatient, PE- physical exam, PP- private practice, 
Pt- patient, QED- quasi-experimental design, SR- systematic review, S/S- sensitivity/specificity, W- weight, WC- waist circumference,  
Appendix F 
Table 2 
Synthesis Table 
Author Chovil Gibson Panagiotopoulos Pringsheim/L Pringsheim/P Rodday Ronsley Ronsley Straker Thompson 
Year 2010 2015 2012 2011 2011 2015 2011 2012 2005 2011 
Design EQS QED CSRS SR/MA SR Survey Survey QED correlational QED 
# of Subjects 14 32 334 35 RCTs 120 studies 362 70 2376 89 192 
LOE V IV III I I V V IV V IV 
IV           
Risperidone    X X      
Olanzapine    X X      
Quetiapine    X X      
Aripiprazole    X X      
Clozapine    X X      
MMP        X  X 
ED HB  X         
ABD Obesity   X      X  
WC   X        
DV           
W    ↑ ↑      
BMI    ↑ ↑      
WC   ↑ ↑ ↑      
WC S/S   ↑      ↑  
Rates of 
monitoring 
       ↑  ↑ 
MetS   ↑      ↑  
Barriers to MM           
Time       X    
KD-Parameters  ↑     X    
KD- interpreting 
lab results 
      X    
KD- MM       X    
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ABD- abdominal, BMI- body mass index, CSRS- cross-sectional retrospective study, DV- dependent variable, ED- educational, FBG- fasting blood glucose, EQS- exploratory 
qualitative study, HB- handbook, HL- health literacy, IP- inpatient, IV- independent variable, KD- knowledge deficit, LOE- level of evidence, MA- meta-analysis, MetS- 
metabolic syndrome, MM- metabolic monitoring, MMTP- metabolic monitoring training program, NC- non-compliance, OP- outpatient, PE- physical exam, PP- private practice, 
Pt- patient, QED- quasi-experimental design, SR- systematic review, S/S- sensitivity/specificity, W- weight, WC- waist circumference,  
responsibility 
Patient NC      X     
Comfort with PE  ↑    X     
Pt HL needs X          
Setting           
Community X     X  X   
IP  X X   X X  X X 
PP      X     
OP      X X    
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Appendix G 
EBP Implementation Model 
Iowa Model of Evidence-Based Practice to Promote Quality Care Iowa  
Model begins 
with identifying 
problem focused 
or knowledge 
focused triggers 
Is this a priority 
topic?
If yes- form team, 
assemble research, 
and critique and  
synthesize.
If no; consider other 
triggers
Is there sufficient 
evidence?
If yes- pilot change
If no-conduct 
research
Is change 
appropriate for 
adoption onto 
practice?
If yes-institute 
change. Monitor and 
analyze structure, 
process, and 
outcomes.
Disseminate results
If no- continue to 
evaluate quality of 
care and new 
knowledge
(Melnyk & Fineout-
Overholt, 2015).
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Appendix H 
Conceptual Framework 
Theory of Planned Behavior 
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Appendix I 
Institutional Review Board 
Exemption Letter 
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Appendix J 
Recruitment of Participants 
Recruitment Letter 
 
Appendix K 
Improving Metabolic Monitoring for Children and Adolescents Receiving Second-
Generation Antipsychotics 
 
Date: 11/1/17 
Dear Participant, 
 
I am a graduate student under the direction of Dr. Annmarie Lyles and Dr. Ann Guthery in the 
College of Nursing and Health Innovation at Arizona State University. 
 
I am inviting you to participate in an evidence-based educational program that will address the 
recommended metabolic monitoring for children who are prescribed second-generation 
antipsychotics and determine if education can improve adherence to metabolic monitoring 
guidelines. This will involve participating in an educational class and completing pre- and post-
education questionnaires. The pre-education questionnaire will be administered prior to the 
educational program and will take approximately 10 minutes to complete. The total time required 
to complete the educational program will be approximately 15 minutes. There will be additional 
time allowed after the educational program to answer any questions you may have. The post-
education questionnaire will be administered three months after the educational program and 
takes approximately 10 minutes to complete.  
 
Your participation in the evidence-based educational program and completion of the 
questionnaires is voluntary. You must be 18 years of age or older to participate in this program. 
Responses to the questionnaires will be used to evaluate the effectiveness of the educational 
program. You can skip questions in the questionnaires if you wish. If you choose not to 
participate or to withdraw from the program at any time, there will be no penalty. There is no 
known risk greater than those associated with everyday types of activity associated with 
participation in this evidence-based educational program.  
 
Your responses on the questionnaires will be anonymous and will not be connected to your name 
or other personal identifying information. You will be asked to create an ID using your favorite 
color, the date of your birth, and the first initial of the place of your birth; my ID for example 
would be Yellow23M. The results of this study may be used in reports, presentations, or 
publications, but your name will not be known or used. 
 
If you have any questions concerning this program, please contact the following team members:  
 
The Office of Research Integrity and Assurance at ASU can be reached at (480) 965-6788.  
Dr. Annmarie Lyles- email: annmarie.lyles@asu.edu   Cell Phone: 608-219-7331 
Dr. Ann Guthery- email: ann.guthery@asu.edu   ASU Phone: 602-496-0794 
Janet Tinkey, RN-  email: jmtinkey@gmail.com  Cell Phone:724-875-2661 
 
Your attendance at the educational session and finishing the pre-education and post-education 
surveys will be considered your consent to participate. 
 
Sincerely, 
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Project Educational Intervention 
Educational Intervention Outline 
Improving Metabolic Monitoring for Children who are Prescribed Second-Generation  
Antipsychotics 
1. Background and Significance 
a. Increase in use of second-generation antipsychotics(SGAs) to treat psychiatric 
disorders in children 
b. Side effects of SGAs 
i. Weight changes significantly assoc. with adverse changes in body 
composition- fat mass and waist circumference (WC).  
ii. Increased levels of fasting glucose  
iii. Dyslipidemia  
iv. Hyperprolactemia 
c. SGA use and increased risk for Metabolic syndrome (MetS) 
d. Increase in risk for cardiometabolic disease in adulthood 
e. Need for routine metabolic monitoring  
f. Poor rates of adherence to metabolic monitoring guidelines are a gap in care for 
children prescribed SGAs 
2. Metabolic Syndrome (MetS) 
a. Definition of MetS: International Diabetes Federation (Nolt et al., 2017) 
b. Abdominal adiposity is a hallmark of MetS and confers reliable degree of sensitivity 
in detecting metabolic changes in children over time (Nolt et al., 2017). 
c. Criteria for diagnosing MetS in  
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i. Children ages 6-10- can only diagnose obesity-- WC ≥ 90th percentile 
ii. Children ages 10-16-- WC ≥ 90th Percentile and two or more of the following: 
triglycerides ≥150 mg/dl, HDL chol <40 mg/dl, systolic BP ≥130 mmHg/ 
diastolic BP ≥85 mmHg or known Type II diabetes or FBG ≥100 mg/dl 
iii. Children ages 16-18 – IDF criteria for diagnosing MetS in adults 
3. Recommended metabolic monitoring 
a. 2004 ADA guidelines  
b. AACAP recommend following ADA guidelines in 2011 
c. CDC chart for WC in cm for children ages 2-19 
4. Managing metabolic side effects (Pearson, 2012) 
a. Determine risk-benefit of psychotropic medication. 
b. Is there a med with fewer SE? 
c. What is the child’s BMI, WC, and overall health? 
d. What are baseline labs and anthropomorphic values? 
e. Consultation with primary care provider  
References 
Nolt, V. D., Kibler, A. V., Wilkening, G. L., & Fabian, T. J. (2017). Second-generation 
antipsychotic utilization and metabolic parameter monitoring in an inpatient pediatric 
population: A retrospective analysis. Paediatric Drugs, 19(2), 139-146. 
doi:10.1007/s40272-016-0209-x 
Pearson, G. S. (2012). Psychopharmacology notes: Managing the metabolic side effects of 
atypical antipsychotics. Journal of Child and Adolescent Psychiatric Nursing, 25, 54-
55. doi: 10.1111/j.1744-6171.2011111.00316.x 
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Appendix L 
Project Instrument 
Pre-intervention Questionnaire 
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Improving Metabolic Monitoring for Children Who Are Prescribed Second-Generation 
Antipsychotics (SGAs) 
Pre-Test 
This questionnaire will ask you to consider how you feel about using metabolic monitoring 
guidelines when caring for pediatric patients who are prescribed SGAs. Your participation in 
completing this questionnaire is voluntary and all your answers will be anonymous and 
confidential.   
Please create an ID for your questionnaire using your favorite color, your date of birth, and the 
first initial of the place of your birth. For example, my ID would be: Yellow23M.  
ID_____________ 
 
First, I would like to ask a few questions about you. 
How old are you? ___________ 
How many years have you been in practice? __________________ 
What is your gender?   1   Male        2   Female      
What is your professional title?   1   MD         2   DO         3   NP 
 
For the following questions, please circle the number that most closely matches your response.  
1. Using metabolic monitoring guidelines during the next three months for my pediatric 
patients who are prescribed SGAs is:  
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Harmful 1 2 3 4 5 Beneficial 
Good Practice 1 2 3 4 5 Bad Practice 
Pleasant for Me 1 2 3 4 5 Unpleasant for me 
Worthless 1 2 3 4 5 Useful 
 
2. During the next three months, I expect to use guidelines for metabolic monitoring for my 
pediatric patients who are prescribed SGAs. 
Strongly 
Disagree Disagree 
Neither 
Disagree or 
Agree 
Agree Strongly Agree 
1 2 3 4 5 
3. Most people who are important to me where I work think that I 
 
Should 1 2 3 4 5 Should Not 
use metabolic monitoring guidelines for my pediatric patients who are prescribed SGAs 
 
4. It is expected of me that I will use metabolic monitoring guidelines for my pediatric 
patients who are prescribed SGAs. 
 
Strongly 
Agree Agree 
Neither Agree 
or Disagree Disagree 
Strongly 
Disagree 
1 2 3 4 5 
 
 
 
5. I feel under social pressure to use metabolic monitoring guidelines for my pediatric 
patients who are prescribed SGAs. 
Strongly 
Agree Agree 
Neither Agree 
or Disagree Disagree 
Strongly 
Disagree 
1 2 3 4 5 
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6. People who are important to me where I work want me to use metabolic monitoring 
guidelines for my pediatric patients who are prescribed SGAs.  
 
Strongly 
Agree Agree 
Neither Agree 
or Disagree Disagree 
Strongly 
Disagree 
1 2 3 4 5 
 
7. During the next three months, I want to use guidelines for metabolic monitoring for my 
pediatric patients who are prescribed SGAs.  
 
Strongly 
Disagree Disagree 
Neither 
Disagree or 
Agree 
Agree Strongly Agree 
1 2 3 4 5 
 
8. I am confident that I could use metabolic monitoring guidelines for my pediatric patients 
who are prescribed SGAs if I wanted to. 
 
Strongly 
Disagree Disagree 
Neither 
Disagree or 
Agree 
Agree Strongly Agree 
1 2 3 4 5 
9. For me to use metabolic monitoring guidelines for my pediatric patients who are 
prescribed SGAs it is:  
 
Easy 1 2 3 4 5 Difficult 
 
10. The decision to use metabolic monitoring guidelines for pediatric patients who are 
prescribed SGAs is beyond my control. 
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Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
11. Whether I use metabolic monitoring guidelines for my pediatric prescribed who are 
prescribed SGAs or not is entirely up to me.  
 
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
12. During the next three months, I intend to use metabolic monitoring guidelines for my 
pediatric patients who are prescribed SGAs. 
 
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
 
I would like to ask you a few more questions. In answering the following questions please 
consider the children and adolescents that you have prescribed second-generation antipsychotics 
for during the past month and circle the answer that describes your usual practice.   
13. When you initiate a new prescription for a second-generation antipsychotic do you 
usually measure a baseline: 
a. Blood pressure  No Yes 
b. Weight   No Yes 
c. Height    No Yes 
d. BMI    No Yes 
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e. Waist circumference  No Yes 
f. Fasting plasma glucose, No Yes 
g. Fasting Lipid Profile  No Yes 
 
14. Do you usually measure the following values 12 weeks after starting a new prescription 
for second-generation antipsychotics? 
a. Blood pressure  No Yes 
b. Weight   No Yes 
c. Height    No Yes 
d. BMI    No Yes 
e. Waist circumference  No Yes 
f. Fasting plasma glucose, No Yes 
g. Fasting Lipid Profile  No Yes 
 
 
I want to thank you for taking the time to complete this survey. 
Appendix M 
Instrument Validity 
Content Validity Tool 
Tool for Assessing the Content Validity of the Theory of Planned Behavior Questionnaire for 
Metabolic Monitoring Guidelines  
 
Please highlight the response that best matches your answer. 
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For Q1.  
1. Using metabolic monitoring guidelines during the next three months for my pediatric 
patients who are prescribed SGAs is:  
Harmful 1 2 3 4 5 Beneficial 
Good Practice 1 2 3 4 5 Bad Practice 
Pleasant for Me 1 2 3 4 5 Unpleasant for me 
Worthless 1 2 3 4 5 Useful 
 
Q1 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q1 is appropriate to assess the provider’s attitudes towards using metabolic monitoring 
guidelines 
Strongly Agree Agree Disagree Strongly Disagree 
  
Q1 is relevant to assess the provider’s attitudes toward using metabolic monitoring guidelines.  
Strongly Agree Agree Disagree Strongly Disagree 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q1? 
______________________________________________________________________ 
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For Q2. 
2. During the next three months, I expect to use guidelines for metabolic monitoring for my 
pediatric patients who are prescribed SGAs. 
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
Q2 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q2 is appropriate to assess the provider’s intention to use guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
Q2 is relevant to assess the provider’s intention to use guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
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Any Suggestions for Q2? 
______________________________________________________________________ 
 
For Q3 
3. Most people who are important to me think that I 
Should 1 2 3 4 5 Should Not 
use metabolic monitoring guidelines for my pediatric patients who are prescribed SGAs 
 
Q3 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q3 is appropriate to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q3 is relevant to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
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Any Suggestions for Q3? 
______________________________________________________________________ 
 
 For Q4 
4. It is expected of me that I will use metabolic monitoring guidelines for my pediatric 
patients who are prescribed SGAs. 
Strongly Agree Agree Neither Agree or Disagree Disagree 
Strongly 
Disagree 
1 2 3 4 5 
 
Q4 is understandable.  
Strongly Agree Agree Disagree Strongly Disagree 
 
Q4 is appropriate to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q4 is relevant to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
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Any Suggestions for Q4? 
______________________________________________________________________ 
 
For Q5 
5. I feel under social pressure to use metabolic monitoring guidelines for my pediatric 
patients who are prescribed SGAs. 
Strongly Agree Agree Neither Agree or Disagree Disagree 
Strongly 
Disagree 
1 2 3 4 5 
 
Q5 is understandable.  
Strongly Agree Agree Disagree Strongly Disagree 
 
Q5 is appropriate to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q5 is relevant to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
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__________________________________________________________________ 
 
Any Suggestions for Q5? 
______________________________________________________________________ 
 
 
 
For Q6 
6. People who are important to me want me to use metabolic monitoring guidelines for my 
pediatric patients who are prescribed SGAs.  
Strongly Agree Agree Neither Agree or Disagree Disagree 
Strongly 
Disagree 
1 2 3 4 5 
 
Q6 is understandable.  
Strongly Agree Agree Disagree Strongly Disagree 
 
Q6 is appropriate to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q6 is relevant to assess the provider’s subjective norms regarding the use of guidelines for 
metabolic monitoring.  
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Strongly Agree Agree Disagree Strongly Disagree 
 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q6? 
______________________________________________________________________ 
 
For Q7 
7. During the next three months, I want to use guidelines for metabolic monitoring for my 
pediatric patients who are prescribed SGAs.  
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
 
Q7 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q7 is appropriate to assess the provider’s intention to use guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
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Q7 is relevant to assess the provider’s intention to use guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q7? 
______________________________________________________________________ 
 
For Q8 
8. I am confident that I could use metabolic monitoring guidelines for my pediatric patients 
who are prescribed SGAs if I wanted to. 
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
Q8 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q8 is appropriate to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
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Q8 is relevant to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q8? 
______________________________________________________________________ 
 
For Q9 
9. For me to use metabolic monitoring guidelines for my pediatric patients who are 
prescribed SGAs it is:  
 
Easy 1 2 3 4 5 Difficult 
 
Q9 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
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Q9 is appropriate to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q9 is relevant to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q9? 
______________________________________________________________________ 
 
For Q10 
10. The decision to use metabolic monitoring guidelines for pediatric patients who are 
prescribed SGAs is beyond my control. 
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
Q10 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
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Q10 is appropriate to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q10 is relevant to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
Any Suggestions for Q10? 
______________________________________________________________________ 
 
For Q11 
11. Whether I use metabolic monitoring guidelines for my pediatric prescribed who are 
prescribed SGAs or not is entirely up to me.  
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
Q11 is understandable. 
Strongly Agree Agree Disagree Strongly Disagree 
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Q11 is appropriate to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
Q11 is relevant to assess the provider’s perceived behavioral control regarding the use of 
guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q11? 
______________________________________________________________________ 
 
For Q12 
12. During the next three months, I intend to use metabolic monitoring guidelines for my 
pediatric patients who are prescribed SGAs. 
Strongly 
Disagree Disagree 
Neither Disagree 
or Agree Agree Strongly Agree 
1 2 3 4 5 
 
Q12 is understandable. 
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Strongly Agree Agree Disagree Strongly Disagree 
 
Q12 is appropriate to assess the provider’s intention to use guidelines for metabolic monitoring.  
Strongly Agree Agree Disagree Strongly Disagree 
 
 
Q12 is relevant to assess the provider’s intention to use guidelines for metabolic monitoring. 
Strongly Agree Agree Disagree Strongly Disagree 
 
 
If you chose Disagree or Strongly Disagree, please indicate why.  
__________________________________________________________________ 
 
Any Suggestions for Q12? 
______________________________________________________________________ 
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